Observational studyBMC cancer2026
Association between serum transferrin and overall survival in cancer patients: a multi-center cohort study.
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTransferrin (Tf), a protein which is responsible for carrying iron in plasma reflected the nutritional status of patients. However, the relationship between serum Tf and survival of cancer patients has not been confirmed by large-scale studies.
methodsThe cohort study includes 5546 patients from 40 clinical centers in China. The hazard ratio (HR) calculated by a Cox proportional hazard regression model is used to examine the association between serum Tf concentration and overall survival (OS). Kaplan–Meier curves are used to assess the relationship between Tf concentration and OS in cancer patients. Interaction analysis is utilized to explore the comprehensive influence of low serum Tf concentration and other factors on OS of cancer patients.
resultsAmong all participants, there are 2567 (46.29%) women and 2979 (53.71%) men. The average age is 63.7 years old. The Tf concentration optimal cut‐off points of cancer patients is 1.92 g/L. Tf concentration is associated with overall cancer survival (HR:1.55,1.40–1.72, P < 0.001). By the multivariable Cox analysis, we find that Tf concentration is an independent risk factor (HR:1.21,1.09–1.36, P = 0.001) after adjusting other factors. For specific cancer types, low Tf concentration(< 1.92 g/L) is associated with poor overall survival of digestive, respiratory cancer, and other cancer patients (all P < 0.05). Low Tf concentration(< 1.92 g/L) has combined effects with male, smoking, low body mass index (BMI) or low albumin on unfavorable OS of cancer patients.
conclusionsOn the basis of cut‐off points in our multi-center cohort, low Tf concentration(< 1.92 g/L) is significantly associated with lower OS in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.